Could milestone deal break the Genzyme-Sanofi deadlock?

Behind the scenes of the public stand-off between Sanofi-Aventis ($SNY) and Genzyme ($GENZ) over the pharma giant's $18.5 billion bid, executives at the Massachusetts-based biotech are reportedly mulling a new deal structure that would open the way for a bidder to acquire the company for a price plus a set of milestones. Report